Sexually Transmitted Diseases (STD), also referred to as Sexually Transmitted Infections (STI) are a growing public health issue with over 1 million cases acquired every day. Highlighted by WHO, rapid, simple to use, financially accessible and quality-assured POC tests are urgently needed to facilitate STD screening and diagnosis, Pluslife STD testing solution consists of CT Test, NG/UU Test, CT/NG/UU Test, Palm-Sized Mini Dock Molecular POC System and 8-Channel Molecular POC System, which can achieve the qualities required by WHO.

Early diagnoses to support effective medical treatment and prevent further transmission can be challenging given the majority of STD cases are asymptomatic. The four most common curable STIs are estimated to generate 374 million new infections each year and therefore intervention programs taken by global health authorities are crucial. Unfortunately, almost all the current STD screening programs are deployed in a centralized format with disadvantages in simple-to-result time, cost and technical requirements, the world has a pressing need for the STD testing revolution, especially in low- and middle-income countries with limited resources.

Pluslife STD testing solution is intended for the detection of sexually transmitted infections (STIs) caused by Chlamydia trachomatis (CT), Neisseria gonorrhoeae (NG) and Ureaplasma Urealyficum (UU), using a fast and simple procedure with only two manual steps. According to global consensus, CT and NG are among the most common STIs, while UU is presented with approximately 70% of sexually active women and men in the global population. Product options presented by Pluslife are STD CT Test, STD NG/UU Test and STD CT/NG/UU Test, a test menu to suit the needs of different regions.   

Clinics and sexual health services in the US and Europe generally require more than a few days of turnover time from samples to results, not to mention resource-limited areas where costs of molecular tests remain the biggest barrier as well as laboratory tests are not accessible at a population level. Recognized as the Next-Generation POC Molecular System by FIND (a strategic partner of WHO), Pluslife acquires a unique position to address problems of current STD screening programs in terms of workflow, adaptability and cost, especially for low- and middle-income countries where healthcare workers are insufficient. 

Pluslife STD tests provide lab-grade PCR results within 35 minutes. Tests can be completed during the patient’s visit and eliminate the need to send samples to laboratories, which will greatly reduce the time between initial testing and treatment. And because of the practicality in point-of-care settings without the high cost of specialized instrumentation and laboratories, cost of each test is decreased remarkably. In conclusion, launching STD screening programs with Pluslife STD Solution can support national and international efforts to have STD screening more affordable and accessible and reduce STI rates significantly.

Pluslife products pave a promising way for the revolution of worldwide STD screening and testing programs. The company will continue to strive to make the next-generation POC molecular testing more ease-of-use, accessible and affordable with a commitment to promoting positive health outcomes in sexual health.